Wolverine Stack (20 mg Vial) Dosage Protocol

Wolverine Stack (20 mg Vial) Dosage Protocol

#dosing-schedule .dr-container > header { margin-bottom: 0 !important; padding-bottom: 0 !important; }
#dosing-schedule .dr-container > header * { margin-bottom: 0 !important; }
#dosing-schedule .dr-container > header::before, #dosing-schedule .dr-container > header::after { content: none !important; display: none !important; }
#dosing-schedule .dr-container > section:first-of-type { margin-top: 0 !important; display: flow-root; }
#dosing-schedule .dr-container > section:first-of-type h2:first-child { margin-top: 0 !important; }
#dosing-schedule .dr-container .wp-block-spacer, #dosing-schedule .dr-container hr { display: none !important; height: 0 !important; margin: 0 !important; border: 0 !important; }

Quickstart Highlights

The Wolverine Stack is a pre-mixed 20 mg vial containing BPC-157 (10 mg) + TB-500 (10 mg) in a 1:1 ratio — the most widely used research peptide combination for musculoskeletal recovery. BPC-157 drives local repair; TB-500 provides systemic healing support. Together they address all three phases of tissue healing.[1][2]

  • Reconstitute: Add 2.0 mL bacteriostatic water → 10.0 mg/mL total blend (5.0 mg/mL each component).
  • Loading dose: 500 mcg total (5 units / 0.05 mL) once daily for 4 weeks.
  • Easy measuring: At 10.0 mg/mL on a U-100 syringe, 1 unit = 0.01 mL ≈ 100 mcg total blend.
  • Storage: Lyophilised: freeze at −20 °C; reconstituted: refrigerate at 2–8 °C; use within 4 weeks.
Wolverine Stack 20mg Vial

Dosing & Reconstitution Guide

Educational loading and maintenance protocol for the Wolverine Stack blend

Loading + Maintenance Protocol (2.0 mL = 10.0 mg/mL)

Phase Total Blend Dose Units (U-100) Volume Frequency
Loading (Weeks 1–4) 500 mcg 5 units 0.05 mL Once daily
Maintenance (Weeks 5+) 500 mcg 5 units 0.05 mL 3× weekly

Each daily 500 mcg dose delivers approximately 250 mcg BPC-157 + 250 mcg TB-500. At 500 mcg/day the 20 mg vial (2.0 mL reconstituted) provides 40 daily doses — enough for a full 28-day loading cycle with 12 days to spare, or exactly 40 doses for a 6-week loading period at 5 days/week. Transition to the 3× weekly maintenance schedule once initial healing goals are met.

Reconstitution Steps

  1. Allow frozen lyophilised vial to reach room temperature (10–15 minutes).
  2. Draw 2.0 mL bacteriostatic water with a sterile syringe.
  3. Inject slowly down the inner vial wall; avoid injecting directly onto the powder cake.
  4. Gently swirl until fully dissolved — do not shake. Solution should be clear and colourless.
  5. Label with reconstitution date and both peptide names; refrigerate at 2–8 °C, protected from light. Use within 4 weeks.

Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Supplies Needed

Plan based on a 4-week loading cycle at 500 mcg once daily (28 injections, 14 mg total blend).

  • Wolverine Stack Vials (20 mg each): 14 mg ÷ 20 mg per vial → 1 vial covers the full 28-day loading cycle.
  • Insulin Syringes (U-100, 0.3 mL / 30-unit preferred): 28 injections → 28 syringes.
  • Bacteriostatic Water (10 mL bottles): 2.0 mL per vial → 1 × 10 mL bottle per vial.
  • Alcohol Swabs: 2 per injection → 56 swabs per 4-week cycle.
Wolverine Stack 20mg
View Supplier
Insulin Syringes
View Supplier
Bacteriostatic Water
View Supplier
Alcohol Pads
View Supplier

Protocol Overview

  • Composition: BPC-157 10 mg + TB-500 10 mg (1:1 ratio) in a pre-mixed 20 mg lyophilised vial.
  • Goal: Comprehensive musculoskeletal tissue repair combining BPC-157’s local healing with TB-500’s systemic reach.[1][2]
  • Schedule: Daily SC injection for 4-week loading, then 3× weekly maintenance.
  • Reconstitution: 2.0 mL BAC water per 20 mg vial → 10.0 mg/mL.
  • Storage: Lyophilised at −20 °C; reconstituted at 2–8 °C; use within 4 weeks.

Dosing Protocol

  • Loading (Weeks 1–4): 500 mcg (5 units / 0.05 mL) once daily SC → ~250 mcg BPC-157 + ~250 mcg TB-500.[1]
  • Maintenance (Weeks 5+): 500 mcg (5 units / 0.05 mL) three times weekly SC.
  • Injection site: Near injury site for BPC-157’s local effect; abdomen or thigh adequate for TB-500’s systemic distribution.
  • Duration: Assess at week 8; extend loading or continue maintenance based on healing progress.

Storage Instructions

  • Lyophilised: Store at −20 °C (−4 °F); protect from moisture and light.
  • Reconstituted: Refrigerate at 2–8 °C. Do not freeze. Use within 4 weeks.
  • Appearance: Clear, colourless solution. Discard if cloudy or particulate.

Important Notes

  • The pre-mixed vial ensures consistent 1:1 dosing of both components — no need for individual reconstitution and mixing.
  • For acute localised injuries, inject subcutaneously within 2–5 cm of the injury site to maximise BPC-157’s local FAK-paxillin effects.
  • WADA-prohibited — both BPC-157 and TB-500 are classified as non-approved peptide hormones (Category S2). Athletes subject to anti-doping rules must not use this stack.
  • Track pain scores (NRS scale), range of motion, and swelling at weeks 2, 4, and 8.
  • The Wolverine Stack can be upgraded to the GLOW or KLOW blend for broader tissue repair and skin/immune support. See KLOW Protocol.

How This Works

BPC-157 and TB-500 address tissue healing through complementary, non-overlapping mechanisms that together cover all three phases of tissue repair:

  • Phase 1 — Inflammatory (Days 1–5): TB-500 down-regulates NF-κB and pro-inflammatory cytokines (IL-6, TNF-α); BPC-157 normalises the NO pathway and reduces prostaglandin E2 — together shortening the inflammatory phase.[2]
  • Phase 2 — Proliferative (Days 5–21): BPC-157 activates FAK-paxillin in tendon fibroblasts and endothelial cells; TB-500 enables cell migration via G-actin sequestration. Both drive angiogenesis to restore blood supply to the injured site.[1]
  • Phase 3 — Remodelling (Weeks 3+): TB-500 reduces myofibroblast persistence, limiting fibrosis; BPC-157 supports collagen organisation and tendon cell maturation for restoration of mechanical strength.

Potential Benefits & Considerations

  • Musculoskeletal repair: BPC-157 orthopaedic review: 35 preclinical studies + 1 human pilot showing benefit in tendon, muscle, bone, and cartilage repair.[1]
  • Systemic reach: TB-500 distributes body-wide after SC injection, supporting healing in multiple tissues simultaneously.[2]
  • Gut protection: BPC-157 component provides additional gut mucosal protection — useful for athletes using NSAIDs during recovery.
  • Complementary mechanisms: Local (BPC-157) + systemic (TB-500) repair is more comprehensive than either peptide alone.
  • WADA status: Both components prohibited in- and out-of-competition. Not suitable for tested athletes.

Lifestyle Factors

  • Maintain adequate dietary protein (1.2–1.6 g/kg body weight) for tissue synthesis.
  • Gentle range-of-motion exercises within pain-free range support capillary ingrowth and fibroblast recruitment.
  • Avoid NSAIDs — they blunt prostaglandin-mediated repair signalling that BPC-157 potentiates.
  • Adequate sleep (7–9 hours) maximises overnight tissue repair processes.

Injection Technique

  • Clean vial stopper and injection site with separate alcohol swabs; allow both to air-dry fully.
  • Using a 29–31 gauge insulin syringe (5/16″ to 1/2″ needle), draw the calculated dose.
  • Pinch a skin fold; insert needle at 45° into subcutaneous tissue (90° acceptable with short needles into a pinched fold)[CDC].
  • Inject slowly over 2–3 seconds; do not aspirate. Withdraw and apply gentle pressure.
  • Rotate sites (abdomen, thighs, upper arms); dispose of syringe in sharps container immediately.

Important Note

This content is intended for educational purposes only and does not constitute medical advice, diagnosis, or treatment. This peptide is not approved for human therapeutic use. For research use only.

References


  • Gwyer D et al. — PMC (2025) — BPC-157 Orthopaedic Review
    — 35 preclinical studies + 1 human pilot: BPC-157 in tendon, muscle, bone, and cartilage repair; FAK-paxillin mechanism
    View Source

  • Goldstein AL & Kleinman HK — Annals of the New York Academy of Sciences (2015)
    — Thymosin beta-4 / TB-500: comprehensive review of repair mechanisms across muscle, tendon, cardiac, corneal, and neural tissue
    View Source

  • Bachem Peptide Technical Guide
    — Handling and Storage Guidelines for Peptides (lyophilised and reconstituted forms)
    View Source

  • CDC — General Best Practice Guidelines for Immunization
    — Subcutaneous injection technique, angle, and site rotation guidance
    View Source